Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2256 articles about Gilead Sciences, Inc.
-
Gilead Sciences, Inc. to Release Second Quarter 2009 Financial Results on Tuesday, July 21, 2009
7/15/2009
-
Gilead Sciences, Inc. to Create 30 Jobs in Cork, Ireland
7/8/2009
-
Gilead Sciences, Inc. Release: European CHMP Adopts Positive Opinion for Aztreonam Lysine
6/26/2009
-
Gilead Sciences, Inc. to Present at the Piper Jaffray 4th Annual Europe Conference on Wednesday, June 24
6/19/2009
-
Gilead Sciences, Inc. to Present at Two Upcoming Investor Conferences
6/3/2009
-
Gilead Sciences, Inc.'s Marketing Authorisation Application for Regadenoson Validated by European Medicines Evaluation Agency
5/29/2009
-
Gilead Sciences, Inc. Announces Changes to Cardiovascular R&D Organization Leadership
5/26/2009
-
New Data for Gilead Sciences, Inc.' Ambrisentan Show Clinical Improvements in a Diverse Pulmonary Hypertension (PH) Population
5/18/2009
-
Gilead Sciences, Inc. to Present at the Deutsche Bank 34th Annual Healthcare Conference on Tuesday, May 19
5/18/2009
-
Gilead Sciences, Inc. Files Second Patent Infringement Lawsuit Against TEVA Pharmaceuticals USA
5/15/2009
-
Gilead Sciences, Inc. Profit Rises a Higher-than-Expected 21 Percent
4/22/2009
-
Gilead Sciences, Inc. Initiates Phase II Clinical Trial of Integrase-Based, Single-Tablet, Once-Daily Regimen for the Treatment of HIV
4/17/2009
-
Gilead Sciences, Inc. to Release First Quarter 2009 Financial Results on Tuesday, April 21, 2009
4/15/2009
-
Gilead Sciences, Inc. Successfully Completes Tender Offer for Shares of CV Therapeutics, Inc. With Over 88 Percent of Shares Tendered
4/15/2009
-
Phase III Data for Gilead Sciences, Inc.'s Darusentan Accepted as Late-Breaker Presentation at American Society of Hematology 2009
4/13/2009
-
Gilead Sciences, Inc. Announces Notification of ANDA Filing for Atripla(R)
4/7/2009
-
Gilead Sciences, Inc. Phase III Clinical Trial of Darusentan for Resistant Hypertension Meets Primary Endpoints
4/3/2009
-
Gilead Sciences, Inc. Announces Early Termination of Hart-Scott-Rodino Waiting Period
4/1/2009
-
Gilead Sciences, Inc. Initiates Phase II Clinical Trial of Cicletanine for the Treatment of Pulmonary Arterial Hypertension
3/25/2009
-
European CHMP Adopts Negative Opinion on Gilead Sciences, Inc.'s Aztreonam Lysine
3/19/2009